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Circulating cell-free DNA (cfDNA) is DNA released from necrotic or apoptotic cells 
into the bloodstream(1). Whilst both healthy cells and cancer cells release cfDNA, 
tumours are associated with higher levels of tumour-derived circulating cell-free 
DNA (ctDNA) detectable in blood(2). Absolute levels of ctDNA, as well as genetic 
mutations and epigenetic changes detected in ctDNA show promise as potentially 
useful biomarkers of tumour biology, progression, and response to therapy(2). 
Moreover, studies have demonstrated the discriminative accuracy of ctDNA levels for 
diagnosis of gastrointestinal cancer compared with benign inflammatory diseases(3). 
Therefore, ctDNA detected in blood offers a minimally invasive, easily repeated 
“liquid biopsy” of cancer(4, 5), facilitating real-time dynamic analysis of tumour 
behaviour that could revolutionise both clinical and research practice in oncology(2, 
6).  
 
In this review, we provide a critical summary of the evidence for the utility of ctDNA 







Circulating cell-free DNA (cfDNA) is DNA released from necrotic or apoptotic cells 
into the bloodstream(1). Whilst both healthy cells and cancer cells release cfDNA, 
tumours are associated with higher levels of cfDNA detectable in blood (average 
180ng/mL, ranging from 0->1000ng/mL) compared with healthy controls (average 
30ng/mL, ranging from 0-100ng/mL)(7). Within these ranges there is considerable 
variability between individuals, in part influenced by underlying the inflammatory 
state(7). cfDNA derived from tumour cells is termed circulating cell-free tumour 
DNA, or ctDNA(2). cfDNA is highly fragmented, consisting of short segments 
(<185-200bp in length)(8, 9) which are generated by cellular apoptosis and long 
fragments (200bp-21kbp) generated by necrosis, the latter being more prevalent in 
ctDNA in the presence of cancer(1). ctDNA is therefore distinguishable from cfDNA 
using this method, as well as the presence of genetic alterations present in tumour 
cells but not healthy cells. ctDNA is rapidly cleared from serum and plasma and 
therefore represents a highly dynamic marker of tumour biology(10, 11). However, 
studies have shown that mutations detected in ctDNA do not correspond perfectly 
with those identified in primary tumour tissue DNA, particularly for early-stage 
tumours. Contributing factors to this current limitation in ctDNA detection are that 
copy numbers of ctDNA are generally very low compared with copy numbers of wild 
type cfDNA, and limitations in accuracy of current sequencing technologies limit 
sensitivity for detecting specific mutations in cancer(2, 12). Additionally, tumour cells 
prone to release of ctDNA may be genetically different to the majority populations 




There are several ways in which cfDNA provides invaluable genomic data for clinical 
studies. Absolute levels of ctDNA and genetic point mutations within ctDNA detected 
using point mutation targeted assays, whole exon genetic sequencing or even whole 
genome sequencing techniques provide invaluable genomic data. Additionally, 
epigenetic changes such as hypermethylation of CpG residues can also be determined. 
These alterations in ctDNA in blood at baseline and over time are potentially useful 
biomarkers of tumour biology, progression, and response to therapy(2, 6). Whilst 
evidence shows cfDNA levels are also elevated in inflammation(7, 13) and 
trauma(14), several studies have demonstrated the discriminative accuracy of ctDNA 
levels in patients with gastrointestinal cancer compared with patients with benign 
inflammatory diseases(3, 15-17). Therefore, ctDNA detected in blood offers a “liquid 
biopsy” of cancer(4), potentially obviating the need for invasive tumour biopsy in 
some clinical scenarios and facilitating dynamic, repeated evaluation of tumour 
characteristics(2, 7). 
  
Tumour biopsy is invasive, painful and carries a risk to patients of complications such 
as bleeding and damage to neighbouring structures. Moreover, tumour biopsies may 
only sample one area of tumour and miss important biological information due to 
tumour heterogeneity. Some tumours such as pancreatic cancer are difficult to access 
and therefore repeated sampling of tumours to monitor for prognostic mutations is not 
practical. ctDNA therefore has the potential to revolutionise both clinical management 
and research in oncology by offering patients a rapid, minimally invasive means of 
monitoring tumour behaviour(5), which through being more acceptable to patients, 
may also improve adherence to tumour management strategies . The non-invasive, 
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easily repeatable nature of ctDNA detection also offers considerable benefits for 
large-scale participation in gastrointestinal cancer research studies. 
 
In this review, we provide a critical summary of the evidence for the utility of ctDNA 
as a diagnostic and prognostic biomarker in gastrointestinal malignancies.  
 
Methods of quantifying cfDNA levels, gene mutations and gene methylation 
  
Significant advancements have been made in cfDNA detection and quantification 
methods in recent years and there are several excellent reviews and many papers 
describing technical aspects of cfDNA quantification and ctDNA mutation detection 
to which we direct the reader(2, 6, 7, 18-20). Methodology will therefore not be 
discussed in detail in this review. A brief summary of the process of cfDNA isolation, 
ctDNA mutation detection and methylation pattern determination is provided in 
Figure 1.  
 
Briefly, cfDNA is isolated from plasma or serum and analysed qualitatively using 
older fluorescence-based methods for cfDNA detection, or increasingly by using 
quantitative, highly sensitive digital polymerase chain reaction (PCR)(7). Allele-
specific targeted mutation analysis digital PCR methods allow detection of pre-
specified gene mutations to distinguish ctDNA from wild-type cfDNA(21), whilst 
massively parallel sequencing microfluidic techniques and duplex sequencing coupled 
with next generation sequencing allow efficient, sensitive sequencing of the entire 
genome(7, 20). It is possible to detect down to 0.01-0.001% of mutation allele 




Short interspersed nucleic acid elements (ALU) repeats and long interspersed 
nucleotide elements (LINE1) are non-coding repetitive DNA sequences distributed 
throughout the genome that are used to calculate the DNA integrity index in 
cfDNA(7, 23). ALU115 fragments reflect cfDNA of healthy cell origin, whereas 
ALU247 fragments are more frequently detectable in ctDNA(24, 25). This is an older 
method for distinguishing ctDNA from wild-type cfDNA, is less sensitive and is not 
widely used now that digital PCR techniques have improved sensitivity and 
specificity. Relative telomere length is another technique used infrequently in ctDNA 
studies, where the length of telomere repeat sequences distinguishes ctDNA from 
wild-type cfDNA(26). 
 
DNA methylation modifies gene expression, genomic imprinting and chromosome 
structure and stability(27, 28). Methylation of cytosine residues in dinucleotide CpG 
sites and is detectable using bisulphite conversion(28, 29) and subsequent 
methylation-specific digital PCR (MSP) (30). Panels of methylation markers for use 
in MSP have been developed for gene mutations commonly found in malignancy, 
akin to what have been developed for gene mutation digital PCR. 
 
DNA has also been isolated from free circulating tumour cells in plasma to allow 
more specific clonal information about tumour cells independently of normal host 
cells(2). However, this technique is beyond the scope of this review. 
 





A landmark paper by Bettegowda et al(6) evaluated the diagnostic utility of ctDNA in 
a number of different malignancies in a large sample of 640 patients. Their method 
used next generation sequencing of tumour tissue DNA to determine target mutations, 
which were then quantified in plasma ctDNA using RT-PCR(6). Over 75% of patients 
with advanced stage hepatocellular carcinoma, colorectal cancer, pancreatic cancer, 
stomach and oesophageal cancer had detectable ctDNA in plasma(6). In 223 patients 
without metastatic disease, ctDNA was detected in 73% of CRC, 57% of gastro-
oesophageal cancers and 48% of pancreatic cancers(6). This paper established the 





CRC is the fourth most common malignancy with a global incidence of 17.2 cases per 
100,000. CRC follows a stereotyped progression from premalignant polyp through to 
dysplasia, carcinoma in site and then carcinoma, associated with gradual accrual of 
genetic mutations. Stage I and II CRC are usually curable and only metastatic 
advanced stage IV disease has high mortality. Chromosomal instability with 
mutations in mismatch repair genes and loss of heterozygosity in the APC pathway 
are the most common mutations associated with adenoma development, with 
subsequent KRAS, BRAF, PIK3CA, PTEN, TP53, BAX and TGF-β mutations 
facilitating progression to carcinoma(31). Currently, premalignant adenoma and 
carcinoma screening is performed by colonoscopy, which provides easy access to 
tumour tissue for genetic biomarker analysis. However, patient preference for blood-
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based testing instead of procedural screening tests and the drive for cost-effective 
CRC screening and diagnosis have led to much research into blood-based biomarkers 
in CRC.  
 
The greatest volume of evidence for the diagnostic and prognostic utility of ctDNA 
detection in gastrointestinal malignancy exists for colorectal cancer (CRC) (Table 1).  
 
Diagnosis and Screening in CRC 
 
Levels of both overall cfDNA and tumour-specific ctDNA have been shown in 
multiple studies to be higher in patients with CRC compared with healthy 
controls(32-36) and appear to distinguish early-stage tumours from benign lesions 
with considerable accuracy (36, 37). In one study of 118 CRC patients, 49 with 
polyps and 26 healthy controls, cfDNA levels had a diagnostic accuracy of 80% for 
early-stage CRC compared with benign gastrointestinal disease (36).  
 
ALU247 fragment concentration is higher in plasma ctDNA from CRC patients 
compared with healthy controls (23). A small pilot study reported the combination of 
LINE1, ALU247, ALU115 and mitochondrial DNA detection in plasma ctDNA had 
an AUC of 0.8 for CRC diagnosis alone, rising to 0.9 (PPV of 81% and an NPV of 
74%) when combined with carcinoma-embryonic antigen (CEA) measurement (38). 
A recent large study by Hao et al(39) of 205 patients with CRC, 63 with polyps and 
110 healthy controls found ALU115 and ALU247/115 ratio in ctDNA were 
significantly higher in CRC patients and patients with adenomas compared with 




Kirsten rat sarcoma viral oncogene homolog protein (KRAS) mutations are common 
in CRC (40-50%)(40, 41), occur early in the carcinogenic pathway(42) and have 
frequent mutation “hotspots” in codons 12 and 13 (43), making KRAS an attractive 
marker for CRC diagnosis. In a study of 58 patients with CRC, Lecomte et al(44) 
found 78% of patients with CRC had detectable ctDNA; 38% had KRAS mutations in 
tumour specimens, in whom 45% also had these mutations detectable in ctDNA(44). 
In a further study of 106 patients with metastatic CRC, Thierry et al(45) tested for 7 
different common point mutations in the KRAS gene in plasma ctDNA and found 96% 
concordance between KRAS mutations in ctDNA and matched tumour specimens(45). 
Sensitivity of detecting KRAS mutations in ctDNA was 92% and specificity was 98%. 
However, two small studies have demonstrated KRAS mutations in ctDNA in 35% (22 
of 62) patients with benign colorectal disease(46) and 50% (2 of 4) of patients with 
longstanding ulcerative pancolitis(47), raising concerns about specificity for CRC 
diagnosis but showing potential utility as a diagnostic tool for adenoma premalignant 
lesions. In the latter study, no correlation with mutations in primary tumour DNA was 
undertaken and no follow up of the patients with pancolitis was performed to 
determine outcome. This is a critical point as pancolitis is a strong risk factor for 
CRC, which is often sessile and difficult to diagnose. Moreover, others have found no 
evidence of KRAS mutations in ctDNA from patients with benign gastrointestinal 
diseases (16).  
 
Mutations in the Adenomatous Polyposis Coli (APC) gene are also common in CRC 
(60-70%), occur early in carcinogenesis and over 80% occur in exon 15(48). APC 
mutations in ctDNA significantly correlated with stage of CRC disease in one 
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study(49), however mutations in the primary tumour were not evaluated. Tumour 
Protein 53 (TP53) is also commonly mutated in CRC (60-70%)(50, 51), however it is 
a late event in CRC and there are no hotspot sites for mutation, making it a less useful 
marker for early diagnosis(1). Studies suggest TP53 mutation detection rates of less 
than 15% in ctDNA, however in those with known mutations in tumour the detection 
rate is approximately 40%(1, 52). One small study reported BRAF1 mutations in 
ctDNA and matched primary tumour specimens from CRC patients compared with 
healthy controls (53). This was confirmed by Thierry et al(45), who found 96% 
concordance in BRAF mutations between ctDNA and tumour specimens. However, 
BRAF mutations do not occur frequently in early CRC and therefore may have limited 
diagnostic utility.  
 
Abnormal gene methylation patterns are common in CRC and appear to be an early 
event in carcinogenesis, with good potential as biomarkers for diagnosis and 
screening(54, 55). Around 25% of CRC tumours have evidence of gene 
hypermethylation and 40% of these are detectable in ctDNA(1). One small study 
compared overall ctDNA gene methylation between 24 CRC patients, 10 patients 
with benign gastrointestinal disease and 56 healthy controls(56). High levels of 
overall DNA methylation were seen in both CRC and benign colorectal disease(56), 
demonstrating poor specificity of DNA methylation alone as a marker for CRC 
diagnosis.  
 
Septin 9 (SEPT9) methylation in ctDNA is one of the best-validated biomarkers in 
colorectal cancer. SEPT9 methylation is present in over 90% of CRC specimens, and 
has been well validated in several large, well-designed studies using ctDNA, with a 
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sensitivity of 68-79.3% and specificity of 84.8-89% for CRC diagnosis compared 
with healthy controls(57-61). In several large studies, SEPT9 methylation in ctDNA is 
evident in 69 to 88% of CRC, 30% of benign adenomas and 8-14% of healthy 
controls(57, 60, 62). In another study of 92 CRC cases (25 stage I tumours and 67 
stage II to IV tumours) and 92 controls, SEPT9 was positive in 96.4% of left-sided 
CRC and 94.4% of right-sided CRC(57). By contrast, only 50% of right-sided 
tumours were detected using standard faecal-occult blood testing (FOBT) methods 
and 41.7% using CEA. This is clinically significant as right-sided tumours are more 
likely to be asymptomatic and missed by routine screening methods(57).  
 
A well-designed study by Church et al(63) prospectively assessed the utility of 
methylated SEPT9 for CRC screening of a large cohort of 7,941 asymptomatic 
individuals over 50 years of age using a commercial assay. 53 patients were found to 
have CRC and methylated SEPT9 had sensitivity of 48.2% and specificity of 91.5% 
for overall diagnosis of CRC, with sensitivity values of 35.0%, 63.0%, 46.0% and 
77.4% for stage I-IV disease respectively(63). Additionally, they found methylated 
SEPT9 only had 11.2% sensitivity for detection of advanced adenomas(63). Others 
have shown SEPT9 is infrequently detected in adenomas greater than 1cm in size 
(20%), and has lower sensitivity (14%) than stool DNA sensitivity (82%) for 
diagnosis of large adenomas in screening populations(59, 62, 64). Another large study 
found stool DNA had greater sensitivity and specificity for CRC diagnosis than serum 
methylated SEPT9 in ctDNA(64). These studies clearly demonstrate that SEPT9 alone 
is not a suitable screening marker for CRC, though it may have additional benefit in 




An interesting study by Ladabaum et al(65) evaluated the cost-effectiveness of SEPT9 
as a screening blood test for colorectal cancer in comparison to current screening 
strategies, including faecal occult blood testing (FOBT), faecal immunohistochemical 
testing (FIT), sigmoidoscopy and colonoscopy(65). SEPT9 was cost-effective in 
comparison to no screening, but was inferior to other screening strategies. The cost-
effectiveness of SEPT9 and similar ctDNA-based markers would improve if they 
increased uptake and longitudinal adherence to screening(65).  
 
A large study by Lee et al(17) evaluated methylation patterns in ten genes using 
matched primary tumour tissue and plasma ctDNA from 243 early-stage CRC cases, 
64 patients with colonic adenomas and 276 healthy controls. They found aberrant 
gene methylation patterns in promoters of p14 (18%), p16 (34%), APC (27%), Death 
Associated Protein Kinase (DAPK) (34%), Helicase-Like Transcription Factor 
(HLTF) (32%), human MutL Homolog 1 (hMLH1) (21%), 0,6-Methylguanine-DNA-
Methyltransferase (MGMT) (39%), Retinoic Acid Receptor Beta 2 (RARbeta2) (24%), 
Ras-Association Domain Family Member 2A (RASSF2A) (58%) and WNT Inhibitory 
Factor-1 (Wif-1) (74%) in CRC patients compared with those with benign disease and 
healthy controls (17). Whilst the methylation score for each individual gene had a 
sensitivity of less than 40%, by using a diagnostic cut-off methylation score of 1.6 in 
a model that included APC, MGMT, RASSF2A and Wif-1, the sensitivity of cfDNA 
methylation detection was 85.6% and specificity was 92.1% for CRC diagnosis, with 
a positive predictive value of 90.6% and a negative predictive value of 88.8%(17). 
Wif-1, RASSF2A, p16 and HMLH1 hypermethylation in ctDNA of CRC patients has 
also been reported by others(44, 66-71). HMLH1 promoter hypermethylation appears 
to be an early event in carcinogenesis (66, 67). Others have also identified 
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hypermethylation of Neuropeptide Y (NPY) (sensitivity 97%, specificity 47%), 
Proencephalin (PENK) (95% sensitivity, 61% specificity) and Neurogenin 
1(NEUROG1) (sensitivity 61%) in ctDNA as potential diagnostic markers of CRC(69, 
72).  
 
Leary et al described massively parallel sequencing and personalised analysis of 
rearranged ends (PARE) in matched tumour and ctDNA specimens to identify 
somatic structural variants (including gene copy number alterations and 
rearrangements) (12, 20) for personalised cancer monitoring with greater sensitivity 
than other methods (0.001% variant detection in ctDNA)(20). Whilst structural 
variants are rare in healthy cells and almost ubiquitous in cancer, they are highly 
unique between tumours and their utility is therefore confined to personalised tumour 
monitoring rather than diagnosis and screening.    
 
Finally, microsatellite instability and loss of heterozygosity is a common feature in 
CRC and reflects defective DNA repair mechanisms(73). Evidence of microsatellite 
instability is evident in plasma ctDNA in approximately 35% of CRC patients(1). A 
small study found 16 of 27 (59%) patients who had CRC tumours with confirmed 
microsatellite instability also had detectable markers of microsatellite instability in 
ctDNA(74). However, detection artefacts and high false positive rates for detection in 
ctDNA are likely to limit its utility as a diagnostic marker of CRC(1).  
 
To summarise, these studies collectively demonstrate utility of both ctDNA levels and 
gene mutations for the diagnosis of CRC compared with the healthy state. However, 
non-invasive detection of colonic adenomas to triage the need for colonoscopic 
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removal using ctDNA would also be desirable, and there is currently less evidence to 
support the utility of ctDNA techniques for distinguishing benign adenomas from the 
healthy state. Therefore, this should be an active area of research in future studies in 
CRC. 
 
Prognosis in CRC 
 
A small prospective study found KRAS mutations and RASSF2A hypermethylation in 
ctDNA were associated with reduced disease-free survival at one year in patients with 
metastatic CRC receiving chemotherapy(71). A larger study of KRAS mutations in 58 
patients reported two year survival was only 48% in CRC patients with detectable 
plasma ctDNA, compared with 100% in those without(44). KRAS mutations in 
ctDNA have high diagnostic accuracy for CRC metastases, with sensitivity of 87.2% 
and specificity of 99.2 (6). A further small case-control study identified TP53 
mutations in cfDNA was associated with advanced clinical stage and liver metastases, 
but not lymph node metastases, tumour size or vascular invasion(52). 
 
TAC1 and SEPT9 methylation have prognostic utility in CRC. In a large study of 150 
patients who underwent curative resection for CRC, methylated TAC1 and SEPT9 in 
serum ctDNA were independent predictors of tumour recurrence post surgery and 
cancer-specific mortality and were detectable in blood earlier than CEA levels(75). 
Additionally, hypermethylated HMLH1, HLTF, HPP1 and APC promoters in ctDNA 
are associated with reduced overall survival in CRC in several prospective studies(66, 
67, 70, 76). Others have also reported an association between HLTF and HPP1/TPEF 
hypermethylation and advanced tumour stage(70, 76). Further large prospective 
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Absolute levels of cfDNA predict survival post surgery in CRC, with lower pre-
operative levels associated with greater survival(77, 78). Plasma cfDNA levels rises 
steadily immediately post surgery, perhaps reflecting inflammatory responses(35, 79). 
However, a rapid rise by day 3 post-operatively without a subsequent fall in levels is 
associated with tumour recurrence(34, 35, 78).   
 
KRAS mutations and hypermethylation of p16 in ctDNA have both been associated 
with tumour recurrence post resection (35, 80). In one study, two-year recurrence-free 
survival post curative resection was 66% in patients with detectable ctDNA levels 
compared with 100% in those without detectable ctDNA (44). Importantly, one study 
showed only 3 of 16 CRC patients with post-operative tumour recurrence and KRAS 
mutation detection in ctDNA had elevated carcino-embryonic antigen (CEA) levels, 
suggesting combining ctDNA gene mutation and CEA levels may improve sensitivity 
for post operative recurrence detection.  
 
In a well-designed, small study of 11 CRC patients who had undergone curative 
resection by Reinert et al(81), large somatic structural variants were identified in 
primary tissue specimens using next generation sequencing, then confirmed in plasma 
ctDNA using droplet-digital PCR. They demonstrated ctDNA detection was useful 
post resection for determining completeness of resection, response to adjuvant 
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chemotherapy, recurrence post surgery and development of metastases(81). 
Importantly, using this method allowed early and highly accurate diagnosis of 
recurrence prior to conventional techniques of tumour recurrence surveillance (both 
sensitivity and specificity were 100%). For metastatic disease, detection was an 
average of ten months earlier than conventional follow-up(81).  
 
Taback et al (82) described an interesting technique to improve accuracy of ctDNA as 
a prognostic marker post resection, by isolating ctDNA from mesenteric venous 
samples taken during surgical resection, the hypothesis being that ctDNA levels may 
be higher in mesenteric venous samples due to CRC venous drainage via the 
mesenteric and portal systems. They confirmed that gene hypermethylation was more 
commonly detected in mesenteric (11/11) compared with peripheral plasma samples  
(9/11) (82). This novel technique is straightforward to employ during surgery and 
requires validation in larger studies.  
  
Chemotherapy response and resistance 
 
One of the most exciting applications of ctDNA is for determining tumour treatment 
response and resistance to chemotherapy. KRAS and EGFR mutations conferring 
resistance to EGFR inhibitors can be detected in ctDNA of patients who are failing 
EGRF inhibitor therapy(6, 83). KRAS and BRAF mutations measured in ctDNA prior 
to therapy and quantification of levels during therapy with cetuximab and irinotecan 
predict response to therapy(84, 85) and these mutations are detectable prior to 
radiological evidence of tumour progression (84, 86, 87). Though correlation between 
BRAF mutations in ctDNA and tumour specimens is high, studies have generally 
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found BRAF mutations to be rarely detected in tumour specimens of CRC patients, 
which limits its clinical utility compared with KRAS (36, 85, 88). A recent large study 
of 503 patients with CRC by Tabernero et al(88) confirmed the utility of detecting 
KRAS, BRAF and PIK3CA mutations in ctDNA in CRC patients on regorafenib 
therapy and demonstrated that mutations present in ctDNA change dynamically 
during chemotherapy treatment and may differ to those present in baseline, pre-
treatment tumour samples.   
 
Similarly, overall cfDNA levels have also been used to assess response to neo-
adjuvant chemo radiation in rectal carcinoma. Responders have a significant reduction 
in plasma cfDNA levels after treatment compared with non-responders (89). DNA 
integrity index in cfDNA, measured by ALU repeats, is also an independent predictor 
of response to neo-adjuvant chemo radiation (90). 
 
In summary, there is good evidence from large validation studies that methylated 
SEPT9 and KRAS mutations in ctDNA are useful and accurate markers for CRC 
diagnosis, prognosis including detection of metastatic disease, and for rapid detection 
of post surgical recurrence. KRAS mutations additionally predict response to EGFR-
based biologic agents. Methylated RASSF2A, HMLH1 and Wif-1 may also prove 
useful for diagnosis. Though few studies have specifically evaluated the utility of 
ctDNA in CRC for distinguishing patients with metastatic disease, pilot data suggest 
potential utility of ctDNA for metastatic disease detection in CRC. The time is ripe 
for further studies validating the cost-effectiveness of these markers within current 
management guidelines. However, available data suggest current test sensitivity is 
inadequate for their use as sole screening markers in CRC compared with current 
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screening strategies. Studies validating of combinations of biomarkers with CEA, and 
further assessment of the impact if blood-based biomarkers on CRC screening uptake 




Incidence of oesophageal cancer is 5.9 per 100,000 globally(91) and it has 5-year 
survival rates of only 17% despite treatment. The majority of oesophageal carcinomas 
are adenocarcinoma (10%) or squamous cell carcinoma (90%). Barrett’s oesophagus, 
metaplasia induced by chronic reflux esophagitis, represents the premalignant lesion 
in adenocarcinoma(92). Adenocarcinoma incidence and mortality have been steadily 
increasing over the last decade. The most common genetic mutations in oesophageal 
cancer are TP53, CDKN2A, SMAD4 and ARID1A in adenocarcinoma and TP53, RB1, 
CDKN2A, PIK3CA and NOTCH1 in squamous cell carcinoma(92). Diagnosis and 
screening in Barretts oesophagus is by gastroscopy, which has a low complication rate 
and allows simultaneous treatment options for many lesions as well as ready access to 
genetic material. However, preference for non-invasive approaches to screening and 
monitoring and a lack of other biomarkers provides a potential role for ctDNA in 
oesophageal carcinoma management. 
To date, there have only been a handful of small case-control studies evaluating the 
clinical utility of cfDNA and ctDNA in oesophageal carcinoma. These are 
summarised in Table 2. 
 




Zhai et al (93) conducted genome-wide sequencing in cfDNA and matched tumour 
specimens in a small case-control study of 28 patients (8 with oesophageal carcinoma, 
10 with Barrett’s oesophagitis and 10 healthy controls). They found that ctDNA gene 
methylation profiles correlated significantly (r=0.92) with methylation profiles of the 
primary tumour and identified differences in genetic profiles between oesophageal 
carcinoma, Barrett’s oesophagus and healthy controls(93). This requires further 
exploration in larger cohorts. 
 
Disease prognosis and survival in oesophageal carcinoma  
 
Hypermethylation of the MutS Homolog 2 (MSH2) promoter was identified in 
primary tumour specimens of 101 of 209 patients (48%) with oesophageal squamous 
cell carcinoma, of which 77 patients (76%) had matching findings in plasma ctDNA. 
MSH2 hypermethylation detected in plasma ctDNA predicted reduced disease-free 
survival post oesophagectomy in one study (94), whilst another reported APC 
hypermethylation in ctDNA was associated with reduced survival in oesophageal 
adenocarcinoma, but was not commonly detected (95). Both studies were small and 
had no adjustment for confounding variables.  
 
Current data are insufficient to define the role of ctDNA in oesophageal cancer 
diagnosis and management and further studies are warranted. 
 




The global incidence of stomach cancer is 12.1 cases per 100,000 (91, 96). Early 
stage tumours are curable by resection, however locally advanced disease has only 
25-25% 5-year survival and most patients with metastatic disease survive less than 12 
months despite treatment(96). Common genetic alterations in sporadic gastric cancer 
include altered methylation pattern of the mismatch repair genes and mutations in 
TP53 and HER2/ ERBB2/ EGFR pathways, whereas hereditary cancer syndromes 
including gastric cancer include mutations in APC, TP53, STK11, CDH1 and 
CTNN1A(96). As these mutations represent therapeutic targets with available 
treatments, ctDNA could prove useful for identifying patients most likely to respond 
to systemic targeted therapies or early detection of drug resistance mutations.  
 
Diagnosis of gastric cancer 
  
A summary of current data of blood-based biomarkers in gastric cancer is found in 
Table 2. cfDNA levels are significantly higher in patients with gastric carcinoma 
compared with healthy controls (97, 98). Kim et al (99) found that cfDNA levels had 
a sensitivity of 96.67% and specificity of 94.11% for diagnosis of gastric cancer 
compared with healthy controls when a cut-off of 90ng/mL was used, however cases 
were not early stage tumours and sample size was small.   
 
Studies have found significant association between gastric cancer and promoter 
hypermethylation of the XIAP association factor 1 (XAF1), APC, HMLH1 and Tissue 
Inhibitor of Metalloproteases 3 (TIMP3) genes detected in ctDNA (100, 101). XAF1 
plays a tumour suppressor role in carcinogenesis and is frequently down-regulated in 
gastric carcinoma specimens (100). XAF1 promoter hypermethylation in ctDNA had 
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reasonable accuracy for diagnosis of gastric cancer from healthy controls (AUC of 
0.9) and levels correlated with shorter overall survival in one study (100). Another 
study reported 33 of 60 cancer subjects (55%) and 3 of 22 healthy controls (14%) had 
detectable target gene methylation in serum(101). Promoter methylation was detected 
for APC in 17%, E cadherin in 13%, HMLH1 in 41% and TIMP3 in 17% of gastric 
cancer subjects(101). Furthermore, methylated APC, HMLH1 and TIMP3 
concentrations were significantly associated with stage III and stage IV disease(101), 
while E cadherin and APC combined were associated with shorter overall 
survival(101). However, of concern in this study was the relatively high detection of 
methylated target genes in the healthy control group. This may reflect underlying 
predisposition to gastric cancer and therefore poor specificity of ctDNA for gastric 
cancer diagnosis(101). In addition, ctDNA findings were not confirmed in primary 
tumour specimens. 
 
Another study highlighted increased Sex determining region Box 17 (SOX17) 
promoter methylation in gastric carcinoma, with a trend to shorter overall survival. 
However, this study was small and included no controls (102). RASSF1A promoter 
methylation in ctDNA was also identified in 34% of 47 patients with gastric 
adenocarcinoma compared with 3% of 30 patients with benign gastric disease and 30 
healthy controls (p<0.001), suggesting potential utility as a diagnostic marker for 
gastric carcinoma (68).  ctDNA RASSF1A methylation correlated strongly with 
RASSF1A methylation in tumour specimens(68). 
 
Multimodular adaptor proteins, or MINTS, are members of the X11 family and have 
key roles in cell membrane function and cellular transport. Methylation of MINT2 
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promoter was detected in ctDNA of 39% of 92 patients with gastric carcinoma, 6% of 
48 patients with chronic gastritis and no healthy controls(103). The findings in ctDNA 
were confirmed in matched primary tumour specimens. MINT2 methylation was 
significantly associated with tumour progression, metastatic disease and shorter 
overall survival, making this a potentially valuable diagnostic and prognostic 
biomarker that warrants further study. 
 
Post surgery prognosis and recurrence detection in gastric cancer 
 
Levels of cfDNA fall rapidly after surgery for gastric carcinoma, and recurrent levels 
of detectable ctDNA have been associated with tumour recurrence(99). More 
specifically, others have demonstrated that detectable XAF1 methylation in serum 
ctDNA post resection for gastric carcinoma is associated with tumour 
recurrence(100). 
 
Gastrointestinal Stromal Tumours (GIST) 
 
Several groups have evaluated ctDNA mutation detection as a diagnostic and 
prognostic marker for GIST tumours, however studies have been small and require 
validation. Maier et al(104) found cKIT and Platelet-Derived Growth Factor Receptor 
A (PDGFRA) mutations in ctDNA were common in GIST compared to healthy 
controls. Moreover, mutation concentration in ctDNA was higher in patients with 
active disease compared with those in clinical remission or who responded to therapy. 
Rawnaq et al (105) assessed loss of heterozygosity in twelve polymorphic marker 
regions in 91 patients with recurrent GIST. They found microsatellite instability in 
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ctDNA in 33% (30 of 92) patients with recurrent disease (105). However, 
confounding factors such as age and duration of follow up were not considered. 
Another very small study by Yoo et al(106) identified cKIT mutations in exon 17 
which predicted response to tyrosine kinase inhibitor-based chemotherapy regimens 
in GIST patients.  
 
In gastric carcinoma, current evidence suggests XAF1, HMLH1, RASSF1A, APC and 
TIMP3 methylation are potential diagnostic markers, while XAF1 is also useful for 
post surgical recurrence detection. Methylated MINT2 appears to have both 
prognostic and diagnostic utility in gastric carcinoma, including detection of 
metastatic disease. Further studies validating these markers and defining their clinical 




Pancreatic cancer accounts for 2% of cancers globally with a stable incidence of 1-10 
per 100,000 people(91, 107). It is the eighth most common cause of cancer-related 
death with 5 year survival rates of only 5% as it is frequently clinically silent until 
very advanced, when curative therapies are often no longer (108). Pancreatic cancer 
progresses from premalignant lesions to cancer in similar molecular fashion to CRC. 
Over 90% have KRAS mutations, of which 80% are in exon 12 (109-112). Other 
common rate-limiting mutations as lesions progress include CDKN2A, TP53 and 
SMAD family 4 (SMAD4) mutations (107). Currently there is no effective screening 
tool for premalignant lesions or pancreatic cancer(107). Obtaining pancreatic tissue 
for diagnosis and genetic biomarkers is difficult as it requires either endoscopic 
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ultrasound guided biopsy with an associated risk of tumour seeding, therefore there is 
a potential role for ctDNA to reduce the need for invasive pancreatic biopsy. 
 
The discovery of identical KRAS mutations in both pancreatic tumour specimens and 
ctDNA by Sorenson et al (113) was a pioneer publication in ctDNA research. Their 
findings have been confirmed by various groups A recent paper by Kinugasa et 
al(112) in 75 patients with pancreatic cancer demonstrated KRAS mutations were 
detected in 74.7% of tumour specimens and 62.6% of ctDNA samples. Survival was 
reduced in those with KRAS mutations identified in ctDNA, but not in tissue 
samples(112). Another study of 47 patients with pancreatic cancer and 31 patients 
with chronic pancreatitis reported 47% detection of KRAS mutations in ctDNA in 
pancreatic cancer patients, compared with 13% in patients with chronic pancreatitis, 
with a sensitivity of 47% and specificity of 87% for cancer diagnosis(15). However, 
combining KRAS mutation detection in ctDNA with CA19-9 had a sensitivity of 98% 
and specificity of 77% and negative predictive value of 96%(15). Interestingly, none 
of the four patients with chronic pancreatitis went on to develop pancreatic cancer in 
36 months of follow-up. This study highlights that ctDNA KRAS detection may be a 
useful adjunct to CA199 testing when CA199 results are equivocal(15). 
 
Liggett et al(108) used a microarray methylation detection method for 56 fragments 
(MetDet56) and found methylation patterns in 8 gene promoter regions could reliably 
distinguish pancreatic cancer from healthy controls, with sensitivity of 82% and 
specificity of 78% (108). These genes included Breast Cancer Associated gene 1 
(BRCA1), Cyclin D2 (CCND2), HMLH1, Cyclin Dependent Kinase Inhibitor 1C 
(CDKN1C), Progesterone Receptor (PGR)-distal, PGR-proximal, Spleen Tyrosine 
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Kinase (SYK) and Von Hippel-Lindau (VHL) (108). A second panel of 14 gene 
promoter regions could distinguish pancreatic cancer from chronic pancreatitis with 
sensitivity of 91% and specificity of 91%(108). These genes included CCND2, 
DAPK1, Oestrogen Receptor 1 (ESR1), PromA, HMLH1, MGMT, Mucous gel 
forming protein 2 (MUC2), Myogenic Differentiation 1 (MYOD1), CDKN2B, 
CDNK1C, Phosphoglycerate Kinase 1 (PGK1), PGR proximal, RARbeta, 
Retinoblastoma 1 (RB1) and SYK(108). CDKN1C, CCND2, HMLH1, PGR-proximal 
and SYK were identified in both panels and therefore may provide a simple broad 
marker panel worthy of validation for pancreatic cancer diagnosis (108). In this study, 
ctDNA gene mutations were not compared to those present in the primary tumour. 
 
Yi et al(114) reported sensitivity of 81% and specificity of 95% for the combination 
of methylated Basonuclin 1 (BNC1) and ADAM Metallopeptidase with 
Thrombospondin 1 (ADAMTS1) in ctDNA for diagnosing early-stage pancreatic 
carcinoma, including Pancreatic in-situ Neoplasia (PIN) 3(114). Other small studies 
have reported abnormal methylation of the CCDN2, VHL, Thrombospondin 1 
(THBS1), Suppressor of Cytokine Signalling 1 (SOCS1) and Plasminogen Activator 
and Urokinase (PLAU) genes in pancreatic cancer (115).  
 
In summary, KRAS mutations in ctDNA appear useful for diagnosis of pancreatic 
cancer and can distinguish from chronic pancreatitis, which addresses an important 
clinical diagnostic need. However, detecting combinations of KRAS mutations with 
other biomarkers may improve early stage diagnostic accuracy of ctDNA and 






Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide 
and third most common cause of cancer-related death and has a high mortality despite 
treatment(91, 116). HCC usually develops within background liver disease, usually in 
the presence of cirrhosis. Due to the many potential predisposing aetiologies of liver 
disease, HCC is genetically heterogeneous and involves many molecular carcinogenic 
pathways. Commonly mutated genes include CTNNB1/ APC/ AXIN1, TERT, 
CDKN2A, PIK3CA, TP53 and ARID1 and ARID2 (117). To date, this has been a key 
limitation in the translation of genetic markers in HCC to clinical care. Currently, 
HCC screening is performed using twice yearly ultrasound and diagnosis does not 
require tumour tissue biopsy(116). Therefore, ctDNA would provide an alternate 
means of obtaining genetic information about the tumour in the absence of liver 
biopsy.  
 
There have been several studies evaluating cfDNA and ctDNA utility in 
hepatocellular carcinoma (HCC) management. A summary of available ctDNA data 
in HCC is found in Table 3. 
 
Diagnosis and screening in HCC 
 
Currently available tumour markers for HCC show only moderate sensitivity and 
specificity for HCC. Several studies show cfDNA levels are significantly higher in 
patients with HCC compared with chronic liver disease and healthy controls and 
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reasonable accuracy for distinguishing between HCC and chronic liver disease(118-
123), with reported sensitivity of 56.4% to 69.2% and specificity of 93.3% (118, 121)  
 In these studies, attempts to distinguish ctDNA from cfDNA were not made. 
El-Shazly et al (124) found longer cfDNA fragments were more common in HCC 
cases compared with healthy controls, with DNA integrity more strongly associated 
with HCC diagnosis than cfDNA concentration (124). An interesting study by Fu et al 
(26) found relative telomere length in serum cfDNA was significantly higher in 140 
Hepatitis B (HBV)-related HCC cases without cirrhosis compared with 280 HBV 
infected non-cirrhotic controls and this remained significant on multivariate analysis 
(26). Large sample size and statistical adjustment for clinical confounders make this a 
strong study design and further assessment of telomere length in cfDNA in non-
cirrhotic HCC should be prioritised. 
  
Whilst gene mutations are very common in HCC, they are highly varied, with most 
gene alterations reported in less than 30% of tumours and few “hot spots” of frequent 
mutation. Tumour suppressor TP53 249Ser is one exception, a “hotspot” mutation 
very commonly associated with aflatoxin exposure, HBV infection and HCC. It 
occurs predominantly in south Asia and sub-Saharan Africa, where exposure to 
aflatoxin through groundnut consumption is high (122).  However, this mutation is 
very uncommon in Caucasian HCC populations(122, 125). There are several high 
quality genetic epidemiology studies published by Kirk et al demonstrating a strong 
association between ctDNA TP53 mutation Ser249 and hepatitis B (HBV)-related 
HCC in Gambians and this correlates closely with serum aflatoxin adduct levels (122, 
126-128). The largest of these studies detected the mutation in 74 of 186 HCC cases, 
15 of 98 patients with HBV-related liver cirrhosis and 12 of 348 HBV infected 
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controls, with an odds ratio of 20.3 for HCC (122). This study was particularly 
important for highlighting the potential utility of ctDNA for diagnosis of HCC in 
resource-poor settings. However, mutations that predispose to HCC and pre-date 
HCC development are unlikely to be highly specific for HCC diagnosis and may be 
better suited to HCC risk stratification for the purposes of screening. This study also 
described confounding adjacent gene mutations that affected the accuracy of TP53 
249Ser mutation assays, highlighting an important potential cause of reduced 
diagnostic sensitivity of ctDNA point mutation analysis for HCC diagnosis (122).  
 
There have been few other studies of ctDNA gene mutations in HCC. An Egyptian 
case-control study reported low levels of TP53 detection and an absence of CTNNB1 
mutations in ctDNA of HCC patients of mixed aetiology, and these findings were 
confirmed in primary tumour tissue specimens in a smaller subset of patients (119).  
 
Promoter methylation of RASSF1A occurs in up to 70% of HCC patients compared 
with patients with chronic liver disease and healthy controls (6-8% RASSf1A 
hypermethylation) (30, 129-132). Importantly, several groups have found elevations 
in methylated RASSF1A as well as p15 and p16, APC, Fragile Histidine Triad (FHIT) 
and E cadherin (30, 133) in ctDNA pre-dates HCC diagnosis (30, 132). Overall 
accuracy of RASSF1A, p15 and p16 methylation detection in ctDNA for HCC 
diagnosis was 89% (sensitivity of 84% and specificity of 94%), after adjusting for 
confounding variables (30).  
 
Hypermethylation of G protein-coupled bile acid receptor GPBAR1 (TGR5) in 
ctDNA was significantly more common in HCC cases (77/160) compared with 
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chronic hepatitis B infection (12/88) and healthy controls (2/45) in one large study 
(134). When combined with alpha-fetoprotein, TGFR5 significantly improved 
sensitivity for diagnosis of HCC (81.25% for AFP cut-off of 20ng/mL), however, this 
was at the expense of reduced specificity (38.64%). Interestingly, there was 
significantly greater methylation in those over 60 years of age, confirming the 
importance of adjusting for confounding factors such as age in gene methylation 
studies (134).  By contrast, hypomethylation of LINE1 repeats in ctDNA is more 
common in HCC cases compared with cirrhosis and healthy controls, though 
diagnostic accuracy has not been assessed(24). 
 
Prognosis in HCC 
 
Several studies have reported significant associations between overall cfDNA levels 
and tumour differentiation and tumour size (121, 135), as well as a negative 
association with 3 year disease-free survival(135). In a large study of 87 HCV-related 
HCC with chronic HCV infection, Tokuhisa et al(120) found high cfDNA levels were 
an independent predictor of shorter overall survival and distant metastases after 
hepatectomy on multivariate analysis. However, in another cohort of 96 HCV-related 
HCC and 99 chronic HCV controls not undergoing surgery, the same group found no 
association between cfDNA levels and tumour size, stage or overall prognosis (123). 
Interestingly, they found that cfDNA levels correlated with inflammatory cytokine 
gene expression (123).  
 
Hypomethylation of LINE1 repeats in ctDNA was an independent predictor of shorter 
overall survival and associated with HBV infection, large tumour size and advanced 
30 
 
CLIP score in one study(24). High DNA integrity has also been shown to be an 
independent marker of shorter overall survival, tumour size, TMN stage, vascular and 
lymphatic invasion and distant metastases (124). 
 
Two markers of microsatellite instability D8S258 and D8S264, in combination with 
ctDNA concentration, were independent predictors of overall and 3 year disease-free 
survival in HCC(136). Moreover, D8S258 was independently associated with tumour 
stage, tumour differentiation and vascular invasion (136). 
 
To summarise, available evidence suggests concentration of overall cfDNA and TP53 
249Ser mutation in ctDNA are important diagnostic markers of advanced stage HBV 
and aflatoxin-related HCC in African patients, but not in caucasians. cfDNA levels 
appear prognostic for both advanced disease stage and metastases, whilst RASSF1A, 
p15 and p16 methylation appear promising diagnostic markers for early-stage HCC. It 
is important to note that few large validation studies have been conducted of ctDNA 
in HCC patients. Future studies should also include sub-analyses of different 
aetiologies of HCC.  
 
Considerations for the design of future studies 
 
There are three main limitations common to many studies investigating ctDNA 
detection in gastrointestinal malignancy. The first is lack of a standardised approach 
to isolation, detection and quantification of cfDNA levels or gene mutations and 
epigenetic changes in ctDNA. cfDNA concentration is higher in serum than plasma 
due to release from cells during coagulation (137-141), however both methods are 
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widely used and results are not comparable. Furthermore, whilst DNA is relatively 
robust, studies have demonstrated degradation in sample quality over time and use of 
historical samples may reduce accuracy for cfDNA quantification and analysis and 
likewise reduce comparability across studies (139, 142, 143). Studies validating 
different techniques in parallel are needed. 
 
Secondly, not all studies have determined gene mutations and gene methylation 
patterns in both ctDNA and matched primary tumour specimens, and few have 
compared ctDNA sequence to germline sequence in non-tumour cells within the same 
subject. For diagnosis, genetic variants ideally must only be present in ctDNA, not 
cfDNA from healthy cells. For prognosis, ctDNA must accurately reflect mutations 
currently present in the primary tumour. These comparisons are essential to establish 
credibility of ctDNA as a dynamic marker of tumour..  
 
The third criticism of many published studies in this field is their small sample size, 
which limits discriminative power to determine the effects of clinical confounding 
variables. For example, studies have shown DNA methylation is independently 
influenced by age, smoking, alcohol consumption, gender, toxin exposure, diet 
(particularly folate intake), physical activity, BMI(144), even socio-economic 
status(28, 145-149). Background polymorphisms can also affect epigenetic 
methylation and tumour phenotype and should be accounted for (150). Aetiology of 
underlying disease may also be a factor influencing the carcinogenesis pathway 
through altered inflammatory mechanisms. Detailed analysis of these potentially 
important clinical variables cannot be performed rigorously without sufficient 
numbers of subjects included. Indeed, development of  
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strict statistical analysis benchmarks for studies in ctDNA akin to bioinformatical 
analysis standards developed for GWAS studies would greatly benefit this field.  
 
Future directions for the practical use of ctDNA techniques in the clinic 
 
Collectively, these data support a potential role for ctDNA at the bedside in 
gastrointestinal malignancy. ctDNA levels and mutation detection has proven utility 
for diagnosis in gastrointestinal malignancy, including more limited evidence for 
diagnosis of premalignant lesions for some cancers (such as colonic adenomas and 
Barrett’s’ oesophagitis) which could allow a screening blood test to triage the need for 
more invasive endoscopy to detect and remove premalignant lesions. Prognostic 
information offered by ctDNA mutation detection could facilitate early detection of 
metastatic disease and personalise treatment algorithms to maximise outcomes. 
ctDNA also provides rapid detection of tumour recurrence post curative therapy, with 
evidence for this in CRC and HCC. Identification of systemic treatment resistance-
conferring genetic mutations in ctDNA also has proven utility in CRC. Moreover, 
development of epigenetic methylation inhibitor therapies means ctDNA gene 
methylation detection may also become an important biomarker for prognosis and 
treatment response. Genetic mutations and altered methylation patterns have proven 
useful for prognosis in CRC, pancreatic cancer and HCC, whereas to date methylation 
changes have been the main biomarker identified in ctDNA in gastro-oesophageal 
cancer.  
 
From a practical perspective, there are still limitations to use of ctDNA in the clinic. 
Cost of whole exome sequencing is currently very high and unlikely to be a cost-
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effective approach in the short term. Moreover, limitations in sensitivity for detecting 
the majority of mutations present in primary tumour tissue in ctDNA still exist, as 
outlined in many of the studies described, particularly for early-stage disease and 
well-differentiated tumours with lower metastatic potential such as HCC. However, 
the rapid pace of genomic technology and associated bioinformatics analysis platform 
developments, coupled with subsequent reductions in sequencing costs over time, 
mean it is likely that these barriers will be overcome and targeted whole exon 
sequencing will become more readily available, with lower detection limits and 
greater sensitivity and specificity for ctDNA detection. Whole exon sequencing will 
also expand the clinical utility of ctDNA in malignancies with greater heterogeneity 
of genetic mutational sequences such as HCC, where individual targeted point 
mutation assays are unlikely to be helpful. However, for malignancies such as CRC, 
targeted combinations of point mutation in panels are likely to prove very useful for 
both diagnosis and prognosis. Targeted mutation assays are also likely to have an 
important role for following individual mutations located in tumour specimens over 
time for early detection of recurrence post curative therapies. Whilst in CRC the 
mutational landscape is well recognised and the future looks bright for translation of 
ctDNA-based technologies into the clinic, for other malignancies such as HCC and 
oesophageal cancer more research is still required to identify the best genetic 
biomarkers for diagnosis and prognosis. Arguably, where ctDNA will prove most 
clinically useful will be malignancies such as HCC and pancreatic cancer, where 
tumour tissue is not routinely obtained or is not recommended due to the potential for 
tumour seeding of biopsy tracts. Finally, how we successfully combine biomarkers 
spanning genomic, metabolomics and proteomic domains and incorporate them into 
current gastrointestinal malignancy screening and management guidelines to 
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maximise early cancer diagnosis and prognosis remains a critically important future 
challenge for translational researchers. Greater translational data quality and cost-
effectiveness analyses will support regulatory changes to allow incorporation of these 




There is a wealth of data supporting the utility of ctDNA for both diagnosis and 
prognosis in various gastrointestinal malignancies, with particularly strong evidence 
for diagnosis and prognosis in colorectal cancer, pancreatic cancer and HCC. 
Monitoring for tumour recurrence post surgery and detection of mutations indicating 
resistance to chemotherapy are two of the most promising clinical uses of ctDNA 
detection. Pilot data also support a role for ctDNA in metastatic disease detection in 
CRC, gastric cancer and HCC. However few studies have specifically evaluated the 
accuracy of ctDNA techniques for distinguishing metastatic from non-metastatic 
disease with sufficient power. Further large-scale validation studies of ctDNA 
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Figure 1A. Development of cancer and relationship to circulating cell-free 
tumour DNA levels (ctDNA) 
ctDNA levels remain low in the healthy state. ctDNA levels increase with the 
presence of adenomas and become increasingly elevated with progression of 
malignancy from carcinoma-in-situ to early-stage cancer. Curative treatment causes a 
rapid fall in ctDNA levels back to baseline levels. However, ctDNA levels are 
detectable in recurrent disease and increase rapidly as advanced carcinoma and 
systemic metastases develop. 
 
Figure 1B. The process of circulating cell-free tumour DNA (ctDNA) 
procurement, genetic analysis and use in the clinic 
A blood sample is taken from the patient in the clinic. Whole blood undergoes 
centrifugation and the plasma or serum supernatant is then isolated, then applied to 
cfDNA isolation columns and a multi-step process of elution and precipitation of 
DNA from plasma occurs.  
ctDNA is then quantified using real-time polymerase chain reaction (PCR). Specific 
gene mutations of interest are detected using allelic imbalance methodology, targeted 
PCR mutation assay, microarray of whole genome Next Generation Sequencing 
(NGS).  
Hypermethylated CpG dinucleotides can be detected by bisulphite conversion of 
DNA. Briefly, bisulphite conversion protocols convert unmethylated, but not 
methylated, cytosine residues to uracil. The modified DNA is then analysed using 
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either methylation-specific polymerase chain reaction (PCR), whole genome 
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